Clinical trials: Demyelinating Disorder
Relapsing-Remitting Multiple Sclerosis, Secondary Progressive Multiple Sclerosis
Safety Study of Natalizumab to Treat Multiple Sclerosis (MS)
The primary objective of this study is to compare the pharmacokinetic (PK) and pharmacodynamics (PD) of single subcutaneous (SC) and intramuscular (IM) doses of 300 mg natalizumab to intravenous (IV) administration of 300 mg…
- Trial name
- NCT00559702
- Testing
- natalizumab, standard of care
- Where
- 12 sites in United States
- Volunteers
- 76 people
- Sponsor
- Biogen
Multiple Sclerosis, Primary Progressive
A Study of Ocrelizumab in Participants With Primary Progressive Multiple Sclerosis
This randomized, parallel group, double-blind, placebo controlled study will evaluate the efficacy and safety of ocrelizumab in participants with primary progressive multiple sclerosis.
- Trial name
- NCT01194570
- Testing
- Ocrelizumab
- Where
- 184 sites in United States, Australia and 27 more
- Volunteers
- 735 people
- Sponsor
- Hoffmann-La Roche
Optic Neuritis
Interest of Dynamic Measures of the Pupil in Optic Neuritis
The investigators' hypothesis is that measuring the PCTdynamics would be an easy and reliable symptom to evaluate in pathologies affecting the optic nerve
- Trial name
- PCT-NORB (NCT02004054)
- Testing
- measure of pupil diameter
- Where
- France
- Volunteers
- 30 people
- Sponsor
- Fondation Ophtalmologique Adolphe de Rothschild
Relapsing-remitting Multiple Sclerosis
Natalizumab De-escalation to Interferon-beta-1b in Patients With Relapsing-remitting Multiple Sclerosis
Multiple Sclerosis (MS) is the most common neurological disorder causing disability in young adults affecting approximately 1 in 1.000 people in western countries.
- Trial name
- NCT01701856
- Testing
- Interferon beta-1b
- Where
- Switzerland
- Volunteers
- 5 people
- Sponsor
- Claudio Gobbi
Multiple Sclerosis
A Study of the Pharmacokinetics and Immunologic Effects of Lipoic Acid in Multiple Sclerosis
The purpose of this study is to learn about an investigational drug known as oral lipoic acid (LA) that may help treat multiple sclerosis.
- Trial name
- NCT00676156
- Testing
- oral lipoic acid (LA), lipoic acid (LA) with fish oil and LA without fish oil, R lipoic acid
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Oregon Health and Science University
Multiple Sclerosis
Effect of High Tone Power Therapy on Bladder Disturbance
This study is conducted to investigate the effect of high-tone power therapy on improving bladder function and quality of life in patients with MS.
- Trial name
- NCT06837675
- Testing
- high tone power therapy, selected physical therapy program
- Where
- Egypt
- Volunteers
- 40 people
- Sponsor
- Cairo University
Progressive Multiple Sclerosis
A Study to Characterize Subcutaneous or Intravenous Alemtuzumab in Patients With Progressive Multiple Sclerosis
Primary Objective: To characterize the pharmacodynamic profile of 2 treatment courses of alemtuzumab administered by subcutaneous injection and 2 treatment courses of alemtuzumab administered by intravenous infusion in patients…
- Trial name
- SCALA (NCT02583594)
- Testing
- Acyclovir, Methylprednisolone, alemtuzumab GZ402673
- Where
- Spain
- Volunteers
- 24 people
- Sponsor
- Genzyme, a Sanofi Company
Multiple Sclerosis, Balance; Distorted
The Effect of Cervical Mobilization on Balance and Spasticity in Multiple Sclerosis Individuals
Taking into consideration the effects of mobilization on muscle tone and balance, it is predicted that this method will have effective results in the treatment of individuals with MS.
- Trial name
- NCT03706131
- Testing
- cervical mobilisation
- Where
- Turkey (Türkiye)
- Volunteers
- 36 people
- Sponsor
- Hacettepe University
Multiple Sclerosis
Robotic -Assisted Rehabilitation for Multiple Sclerosis: An Adaptive Approach for Individualized Therapy
Therefore, the purpose of this study was to evaluate four-weeks of an upper limb robotic intervention for persons with Multiple Sclerosis.
- Trial name
- NCT07070388
- Testing
- end-effector robotic training
- Where
- Canada
- Volunteers
- 9 people
- Sponsor
- Michael Holmes
Erectile Dysfunction Due to Diseases Classified Elsewhere, Multiple Sclerosis, Relapsing-Remitting
Effect of Bio-electromagnetic Energy Regulation Therapy on Erectile Dysfunction in Patients With Multiple Sclerosis
Multiple sclerosis (MS) is an inflammatory disease that affects the brain and spinal cord. There are potential impacts on neurological functions, including sensory and autonomic functions.
- Trial name
- NCT05615454
- Testing
- bio-electromagnetic energy regulation therapy (BEMER) machine model type: B.BOX CLASSIC, model NO: 420100, 12-15 Volt, (BEMER Int.AG, Liechtenstein product).
- Where
- 2 sites in Saudi Arabia
- Volunteers
- 50 people
- Sponsor
- Imam Abdulrahman Bin Faisal University
Multiple Sclerosis
Efficacy of Cholecalciferol (Vitamin D3) for Delaying the Diagnosis of MS After a Clinically Isolated Syndrome
The main objective of this study is to evaluate the efficacy and tolerance of 2 years of treatment with cholecalciferol (vitamin D3) in patients with a clinically isolated syndrome at high risk for MS (CIS).
- Trial name
- D-Lay-MS (NCT01817166)
- Testing
- Vitamin D, Imaging, Lumbar puncture
- Where
- 33 sites in France, Martinique
- Volunteers
- 316 people
- Sponsor
- Centre Hospitalier Universitaire de Nīmes
Multiple Sclerosis, Stroke
Short Arm Human Centrifuge Therapeutic Training and Rehabilitation (GRACER1)
The study is a single blind randomized controlled trial (RCT) designed to examine the benefit of a short arm human centrifuge intervention program (SAHC) combined with exercise, compared to a standard of care (SOC) rehabilitation…
- Conditions
- Multiple Sclerosis, Stroke, Pulmonary Disease, Chronic Obstructive, Aged
- Trial name
- GRACER1 (NCT04369976)
- Testing
- ARTIFICIAL GRAVITY COMBINED WITH EXERCISE
- Where
- Greece
- Volunteers
- 105 people, healthy volunteers welcome
- Sponsor
- Greek Aerospace Medical Association and Space Research
Multiple Sclerosis, Secondary Progressive, Multiple Sclerosis, Primary Progressive
Efficacy and Safety of Masitinib in the Treatment of Progressive Multiple Sclerosis
The purpose of this study is to compare the safety and efficacy of masitinib 6 mg/kg/day versus placebo in the treatment of patients with primary progressive multiple sclerosis or relapse-free secondary progressive multiple…
- Conditions
- Multiple Sclerosis, Secondary Progressive, Multiple Sclerosis, Primary Progressive, Multiple Sclerosis, Relapse Free
- Trial name
- NCT01433497
- Testing
- Masitinib
- Where
- 8 sites in Bulgaria, France and 5 more
- Volunteers
- 656 people
- Sponsor
- AB Science
Multiple Sclerosis
Herbal Therapy for Subcutaneous Injection Site Reactions in Multiple Sclerosis
The purpose of this study is to determine if an herbal over-the-counter cream can decrease skin site reactions in multiple sclerosis patients who currently take either Betaseron, Copaxone or Rebif as their subcutaneous medication…
- Trial name
- MSSkin (NCT00972062)
- Testing
- Bach's Rescue Remedy Cream
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- University of North Carolina, Charlotte
Multiple Sclerosis
An Open-Label, Single-Arm Clinical Study to Evaluate the Safety and Preliminary Efficacy of CD20 Monoclonal Antibody Combined With NK042 Cell Injection in the Treatment of Multiple Sclerosis (MS).
This is an Open-Label, Single-Arm Clinical Study to Evaluate the Safety and Preliminary Efficacy of CD20 Monoclonal Antibody Combined with NK042 Cell Injection in the Treatment of Multiple Sclerosis (MS).
- Trial name
- NCT07546110
- Testing
- NK042, ofatumumab
- Volunteers
- 20 people
- Sponsor
- The Affiliated Hospital of Xuzhou Medical University
Clinical Isolation Syndrome of Spinal Cord, Multiple Sclerosis
Clinical Isolation Syndrome of Spinal Cord and Multiple Sclerosis
The purpose of this study was to investigate the factors that influence the progression of patients with clinically isolated spinal cord syndrome to multiple sclerosis.
- Trial name
- NCT04952246
- Where
- China
- Volunteers
- 150 people
- Sponsor
- Peking University Third Hospital
Optic Neuritis, Myelitis
Treatment of Inflammatory Myelitis and Optic Neuritis With Early vs Rescue Plasma Exchange (TIMELY-PLEX)
The purpose of this research is to evaluate if early vs rescue Therapeutic Plasma Exchange (PLEX) treatment algorithm leads to better visual outcomes in severe Optic Neuritis and leads to better neurological disability outcomes…
- Conditions
- Optic Neuritis, Myelitis, Myelitis, Transverse
- Trial name
- TIMELY-PLEX (NCT07100990)
- Testing
- High-dose corticosteroids (HDCS), High-dose corticosteroids (HDCS) and PLEX
- Where
- 35 sites in United States
- Volunteers
- 382 people
- Sponsor
- Mayo Clinic
Multiple Sclerosis, Relapsing-Remitting
Light Therapy as Treatment for Fatigue in Multiple Sclerosis
This prospective study will randomize 1:1 people living with multiple sclerosis-associated fatigue to one of two spectra of light therapy.
- Trial name
- NCT03060759
- Testing
- Light Therapy box
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Massachusetts General Hospital
Acute Necrotizing Encephalopathy
Clinical and Radiological Prognostic Factors of Acute Necrotizing Encephalopathy in Sohag University Hospital
Acute necrotizing encephalopathy of childhood (ANEC) is a fulminant type of encephalopathy. Most reported cases occur in Asian children with the highest prevalence among patients between the age of 6 and 18 months.
- Trial name
- NCT05853159
- Testing
- Basic Laboratory investigations , Cerebrospinal fluid analysis
- Where
- Egypt
- Volunteers
- 25 people
- Sponsor
- Sohag University
Multiple Sclerosis, Relapsing-Remitting
Impact of the BETACONNECT Auto-injector on BETASERON Therapy Adherence and Patient Satisfaction
The primary objective of this study is to assess adherence and persistence to BETASERON therapy in patients who are using the BETACONNECT auto-injector device (BETACONNECT device).
- Trial name
- NCT02652091
- Testing
- Interferon beta-1b (Betaseron, BAY86-5046), BETACONNECT device
- Where
- 23 sites in United States
- Volunteers
- 146 people
- Sponsor
- Bayer
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.